Jump to ContentJump to Main Navigation
Show Summary Details

Forum for Health Economics & Policy

Editor-in-Chief: Goldman, Dana

2 Issues per year


SCImago Journal Rank (SJR) 2015: 0.216
Source Normalized Impact per Paper (SNIP) 2015: 0.197
Impact per Publication (IPP) 2015: 0.222

Online
ISSN
1558-9544
See all formats and pricing

The Long-Term Impact of Price Controls in Medicare Part D

Gigi Moreno
  • Precision Health Economics, Los Angeles, CA, USA
/ Emma van Eijndhoven
  • Precision Health Economics, Los Angeles, CA, USA
/ Jennifer Benner
  • Precision Health Economics, Los Angeles, CA, USA
/ Jeffrey Sullivan
  • Corresponding author
  • Precision Health Economics, Los Angeles, CA, USA
  • Email:
Published Online: 2017-01-20 | DOI: https://doi.org/10.1515/fhep-2016-0011

Abstract

Price controls for prescription drugs are once again at the forefront of policy discussions in the United States. Much of the focus has been on the potential short-term savings – in terms of lower spending – although evidence suggests price controls can dampen innovation and adversely affect long-term population health. This paper applies the Health Economics Medical Innovation Simulation, a microsimulation of older Americans, to estimate the long-term impacts of government price setting in Medicare Part D, using pricing in the Federal Veterans Health Administration program as a proxy. We find that VA-style pricing policies would save between $0.1 trillion and $0.3 trillion (US$2015) in lifetime drug spending for people born in 1949–2005. However, such savings come with social costs. After accounting for innovation spillovers, we find that price setting in Part D reduces the number of new drug introductions by as much as 25% relative to the status quo. As a result, life expectancy for the cohort born in 1991–1995 is reduced by almost 2 years relative to the status quo. Overall, we find that price controls would reduce lifetime welfare by $5.7 to $13.3 trillion (US$2015) for the US population born in 1949–2005.

Keywords: innovation; Medicare; prescription drugs; price controls; simulation

References

  • Acemoglu, D. and J. Linn (2004) “Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,” Quarterly Journal of Economics, 119(3):1049–1090.

  • Adams, P., M. D. Hurd, D. McFadden, A. Merrill, and T. Ribeiro (2004) “Healthy, Wealthy, and Wise? Tests for Direct Causal Paths between Health and Socioeconomic Status.” In: (David A. Wise, ed.) Perspectives on the Economics of Aging. Chicago and London: University of Chicago Press, pp. 415–518.

  • David, E., T. Tramontin, and R. Zemmel (2009) “Pharmaceutical R&D: The Road to Positive Returns,” Nature Reviews Drug Discovery, 8(8):609–610.

  • DiMasi, J. A. and H. G. Grabowski (2007) “The Cost of Biopharmaceutical R&D: Is Biotech Different?” Managerial and Decision Economics, 28(4–5):469–479.

  • Goldman, D. P., M. Hurd, P. G. Shekelle, S. J. Newberry, C. W. A. Panis, B. Shang, J. Bhattacharya, G. F. Joyce, and D. N. Lakdawalla (2004) Health Status and Medical Treatment of the Future Elderly: Final Report. Santa Monica, CA: RAND Corporation. Available from http://www.rand.org/publications/TR/TR169/.

  • Goldman, D. P., B. Shang, J. Bhattacharya, A. M. Garber, M. Hurd, G. F. Joyce, D. N. Lakdawalla, C. Panis, and P. G. Shekelle (2005) “Consequences of Health Trends and Medical Innovation for the Future Elderly,” Health Affairs, 24(Suppl 2):W5R5–17.

  • Heckman, J. and B. Singer (1984) “A Method for Minimizing the Impact of Distributional Assumptions in Econometric Models for Duration Data,” Econometrica, 52(2):271–320.

  • Lakdawalla, D. N., D. P. Goldman, and B. Shang (2005) “The Health and Cost Consequences of Obesity Among the Future Elderly,” Health Affairs (Millwood), 24(Suppl 2):W5R30–41.

  • Schacht, W. H. and J. R. Thomas (2012) Follow-on Biologics: The Law and Intellectual Property Issues. Washington, DC, USA: Congressional Research Services.

  • Serebrov, M. (2013) “Biologic New Molecular Entities Approvals are Nothing to Write Home About.”

  • Shekelle, P. G., E. Ortiz, S. J. Newberry, M. W. Rich, S. L. Rhodes, R. H. Brook, and D. P. Goldman (2005) “Identifying Potential Health Care Innovations for the Future Elderly,” Health Affairs (Millwood), 24(Suppl 2):W5R67–76.

  • Sood, N., H. De Vries, I. Gutierrez, D. N. Lakdawalla, and D. P. Goldman (2008) The Effect of Pharmaceutical Regulation on Revenues. Santa Monica, CA: RAND Corporation.

  • Truven Health Analytics Micromedex Solutions (2016) RedBook Online. Greenwood Village, CO: Truven Health Analytics.

  • U.S. Food and Drug Administration Center for Drug Evaluation and Research (2014) Novel New Drugs 2013 Summary. Accessed March 25, 2016. Available from http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/DrugInnovation/UCM381803.pdf.

References

  • Abbott, T. A. and J. A. Vernon (2007) “The Cost of US Pharmaceutical Price Regulation: A Financial Simulation Model of R&D Decisions,” Managerial and Decision Economics, 28(4–5):293–306.

  • Acemoglu, D. and J. Linn (2004) “Market Size in Innovation: Theory and Evidence from the Pharmaceutical Industry,” Quarterly Journal of Economics, 119(3):1049–1090.

  • Aldy, J. E. and W. K. Viscusi (2008) “Adjusting the Value of a Statistical Life for Age and Cohort Effects,” The Review of Economics and Statistics, 90(3):573–581.

  • Avalere Health (2016) VA National Formulary Covers 16 Percent Fewer Top Prescription Drugs than Medicare Part D Plans 2015 [cited February 10 2016]. Available from http://avalere.com/expertise/managed-care/insights/a-recent-avalere-analysis-found-that-the-va-national-formulary-covers-fewer.

  • Baker, D. (2013) Reducing Waste with an Efficient Medicare Prescription Drug Benefit. Washington, DC: Center for Economic and Policy Research.

  • Cockburn, I. M., J. O. Lanjouw and M. Schankerman (2014) Patents and the Global Diffusion of New Drugs. London, UK.

  • Congressional Budget Office (2005) Prices for Brand-Name Drugs Under Selected Federal Programs. Washington, DC.

  • Congressional Budget Office (2015) March 2015 Medicare Baseline. Washington, DC.

  • Coulam, R. F., R. D. Feldman and B. E. Dowd (2011) “Competitive Pricing and the Challenge of Cost Control in Medicare,” Journal of Health Politics, Policy, and Law, 36(4):649–689.

  • Cutler, D. (2007) The Lifetime Costs and Benefits of Medical Technology. Cambridge, MA: The National Bureau of Economic Research.

  • D’Angelo, Greg (2016) The VA Drug Pricing Model: What Senators Should Know. The Heritage Foundation 2007 [cited April 11 2016]. Available from http://www.heritage.org/research/reports/2007/04/the-va-drug-pricing-model-what-senators-should-know.

  • Danzon, P. M. and J. D. Ketcham (2004) “Reference Pricing of Pharmaceuticals for Medicare: Evidence from Germany, The Netherlands, and New Zealand,” Forum for Health Economics and Policy, 7(1):1–56.

  • DiMasi, J. A. and H. G. Grabowski (2007) “The Cost of Biopharmaceutical R&D: Is Biotech Different?,” Managerial and Decision Economics, 28(4–5):469–479.

  • Dismuke, Clara E. and Leonard E. Egede (2013) “Medicare Part D Prescription Drug Program: Benefits, Unintended Consequences and Impact on Health Disparities,” Journal of General Internal Medicine, 28(7):860–861.

  • Eber, M. R., D. P. Goldman, D. N. Lakdawalla, T. J. Philipson, D. Pritchard, M. Huesch, N. Summers, M. T. Linthicum, J. Sullivan and R. W. Dubois (2015) “Clinical Evidence Inputs to Comparative Effectiveness Research Could Impact the Development of Novel Treatments,” Journal of Comparative Effectiveness Research, 4(3):203–213.

  • Eger, S. and J. C. Mahlich (2014) “Pharmaceutical Regulation in Europe and its Impact on Corporate R&D,” Health Economics Review, 4:23.

  • Federal Reserve Bank of St. Louis (2016) Consumer Price Index for All Urban Consumers: Medical Care. Federal Reserve Bank of St. Louis, 2016 [cited April 26 2016]. Available from https://research.stlouisfed.org/fred2/series/CPIMEDSL.

  • Filson, D. (2012) “A Markov-perfect Equilibrium Model of the Impacts of Price Controls on the Performance of the Pharmaceutical Industry,” The RAND Journal of Economics, 43(1):110–138.

  • Frakt, A. B., S. D. Pizer and R. Feldman (2012) “Should Medicare Adopt the Veterans Health Administration Formulary?” Health Economics, 21(5):485–495.

  • Gagnon, M.A. and S. Wolfe (2015) Mirror, Mirror on the Wall: Medicare Part D Pays Needlessly High Brand-Name Drug Prices Compared with Other OECD Countries and with U.S. Government Programs Ottowa, ON: Carleton University.

  • Gellad, W. F., S. Schneeweiss, P. Brawarsky, S. Lipsitz and J. S. Haas (2008) “What if the Federal Government Negotiated Pharmaceutical Prices for Seniors? An Estimate of National Savings,” Journal of General Internal Medicine, 23(9):1435–1440.

  • Giaccotto, C., R. E. Santerre and J. A. Vernon (2005) “Drug Prices and Research and Development Investment Behavior in the Pharmaceutical Industry,” The Journal of Law and Economics, 48(1):195–214.

  • Goldman, D. P., D. N. Lakdawalla, J. D. Malkin, J. Romley and T. J. Philipson (2011) “The Benefits from Giving Makers of Conventional ‘Small Molecule’ Drugs Longer Exclusivity over Clinical Trial Data,” Health Affairs, 30(1):84–90.

  • Golec, J. H. and J. A. Vernon (2006) European Pharmaceutical Price Regulation, Firm Profability, and R&D Spending. Cambridge, MA: The National Bureau of Economic Research.

  • Grossmann, V. (2013) “Do Cost-Sharing and Entry Deregulation Curb Pharmaceutical Innovation?” Journal of Health Economics, 32(5):881–894.

  • IMS Institute for Healthcare Informatics (2015) Medicines Use and Spending Shifts: A Review of the Use of Medicines in the U.S. in 2014. Pasipanny, NJ.

  • Jacobson, G. A., S.V. Panangala, and J. Hearne (2007) Pharmaceutical Costs: A Comparison of Departments of Veterans Affairs (VA), Medicaid, and Medicare Policies. U.S. Library of Congress. Congressional Research Service.

  • Kaiser Family Foundation (2016) The Medicare Part D Prescription Drug Benefit 2013 [cited May 18 2016]. Available from http://kff.org/medicare/fact-sheet/the-medicare-prescription-drug-benefit-fact-sheet/.

  • Kaiser Family Foundation (2016) Searching for Savings in Medicare Drug Price Negotiations 2016 [cited February 11 2016]. Available from http://files.kff.org/attachment/issue-brief-searching-for-savings-in-medicare-drug-price-negotiations.

  • Lakdawalla, D. N., D. P. Goldman, P. C. Michaud, N. Sood, R. Lempert, Z. Cong, H. de Vries and I. Gutierrez (2009) “U.S. Pharmaceutical Policy in a Global Marketplace,” Health Affairs, 28(1):138–150.

  • Lambrelli, D. and O. O’Donnell (2011) “The Impotence of Price Controls: Failed Attempts to Constrain Pharmaceutical Expenditures in Greece,” Health Policy, 101(2):162–171.

  • Murphy, K. M. and R. H. Topel (2003) “The Economic Value of Medical Research,” In: (K. M. Murphy and R. H. Topel, eds.) Measuring the Gains from Medical Research: An Economic Approach. Chicago: University of Chicago Press, pp. 41–73.

  • Murphy, K. M. and R. H. Topel (2006) “The Value of Health and Longevity,” Journal of Political Economy, 114(5):871–904.

  • Pharmaceutical Research and Manufacturers of America (2012) PhRMA 2012 Industry Profile. Washington, DC.

  • Pitts, P. J. and R. M. Goldberg (2015) Price vs. Value: The Story and the Rest of the Story. New York, NY: Center for Medicine in the Public Interest.

  • Poterba, J., S. Venti and D. A. Wise (2007) The Decline of Defined Benefit Retirement Plans and Asset Flows. Cambridge, MA.

  • Serebrov, M. (2014) “Biologic New Molecular Entities Approvals Are Nothing to Write Home About,” BioWorld, January 17. Accessed December 21, 2016. Available from http://www.bioworld.com/content/biologic-new-molecular-entities-approvals-are-nothingwrite-home-about-0.

  • Sood, N., H. de Vries, I. Gutierrez, D. N. Lakdawalla and D. P. Goldman (2009) “The Effect of Regulation on Pharmaceutical Revenues: Experience in Nineteen Countries,” Health Affairs, 28(1):125–137.

  • Stroupe, Kevin T., Bridget M. Smith, Timothy P. Hogan, Justin R. St. Andre, Walid F. Gellad, Saul Weiner, Todd A. Lee, Muriel Burk, Francesca Cunningham, John D. Piette, Thea J. Rogers, Zhiping Huo and Frances M. Weaver (2013) “Medication Acquisition across Systems of Care and Patient–Provider Communication among Older Veterans,” American Journal of Health-System Pharmacy, 70(9):804–813.

  • The Board of Trustees of the Federal Hospital Insurance and Federal Supplementary Insurance Trust Funds (2015) 2015 Annual Report of the Boards of Trustees of the Federal Hospital Insurance and Federal Supplementary Medical Insurance Trust Funds. Washington, DC.

  • Tuna, E., K. Atikeler and Z. Calýskan (2014) “Classification of Drugs Bringing from Abroad in Turkey According to Their ATC Codes,” Value in Health, 17(7):A788.

  • U.S. Department of Commerce International Trade Administration (2004) Pharmaceutical Price Controls in OECD Countries: Implications for U.S. Consumers, Pricing, Research and Development, and Innovation. Washington, DC.

  • U.S. Department of Veterans Affairs (2016) Contractor-The Ins and Outs of Public Law 102-585 2015 [cited February 10 2016]. Available from http://www.fss.va.gov/faqs/publicLaw102585.asp.

  • U.S. Food and Drug Adminstration (2014) Novel New Drugs 2013 Summary. Silverspring, MD: Center for Drug and Evaluation Research.

  • Vernon, J. A. 2005. “Examining the Link Between Price Regulation and Pharmaceutical R&D Investment,” Health Economics, 14(1):1–16.

  • Viscusi, W. K., and J. E. Aldy (2003) “The Value of a Statistical Life: A Critical Review of Market Estimates Throughout the World,” Journal of Risk and Uncertainty, 27(1):5–76.

About the article

Published Online: 2017-01-20


Citation Information: Forum for Health Economics and Policy, ISSN (Online) 1558-9544, ISSN (Print) 2194-6191, DOI: https://doi.org/10.1515/fhep-2016-0011. Export Citation

Comments (0)

Please log in or register to comment.
Log in